Origin Therapeutics Holdings (XCNQ:ORIG) EBIT : C$-0.74 Mil (TTM As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings EBIT?

Origin Therapeutics Holdings's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was C$-0.09 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was C$-0.74 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Origin Therapeutics Holdings's annualized ROC % for the quarter that ended in Jun. 2023 was -4,600.00%. Origin Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -4,600.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Origin Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 20.36%.

Origin Therapeutics Holdings EBIT Historical Data

The historical data trend for Origin Therapeutics Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings EBIT Chart

Origin Therapeutics Holdings Annual Data

Trend

Sep21

Sep22

EBIT

-1.02

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBIT	Get a 7-Day Free Trial				-0.22	-0.31	-0.13	-0.21	-0.09

Competitive Comparison of Origin Therapeutics Holdings's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's EV-to-EBIT falls into.

Origin Therapeutics Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.74 Mil.

Origin Therapeutics Holdings (XCNQ:ORIG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Origin Therapeutics Holdings's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-0.368 * ( 1 - 0% )	/	( (0	+	0.016)	/ 2 )
=	-0.368	/	0.008
=	-4,600.00 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.369	-	0.224	-	( 3.326	-	max(0, 0.224	-	3.369	+	3.326	))
=	0

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.191	-	0.11	-	( 3.065	-	max(0, 0.11	-	3.191	+	3.065	))
=	0.016

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Origin Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.368	/	( ( (0 + max(-0.181, 0))	+	(0 + max(0.016, 0)) )	/	2 )
=	-0.368	/	( ( 0	+	0.016 )	/	2 )
=	-0.368	/	0.0079999999999999
=	-4,600.00 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.043	+	0	+	0)	-	(0.224	+	0	+	0)
=	-0.181

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.071	+	0	+	0.055)	-	(0.11	+	0	+	0)
=	0.016

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Origin Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-0.743	/	-3.649
	=	20.36 %

Origin Therapeutics Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.